Valuation: Arvinas, Inc.

Market Cap 497M 446M 412M 373M 697M 47.33B 706M 4.93B 1.96B 24.77B 1.86B 1.83B 78.62B P/E 2026 *
-338x
P/E 2027 * -2.18x
Enterprise Value 46.19M 41.45M 38.32M 34.7M 64.83M 4.4B 65.62M 458M 182M 2.3B 173M 170M 7.31B EV / Sales 2026 *
0.16x
EV / Sales 2027 * 2.96x
Free-Float
79.97%
Yield 2026 *
-
Yield 2027 * -
1 day+2.01%
1 week+0.60%
Current month-1.75%
1 month+1.20%
3 months-7.32%
6 months-25.64%
Current year-35.92%
1 week 7.2
Extreme 7.2
7.7
1 month 6.74
Extreme 6.74
8.04
Current year 6.74
Extreme 6.74
14.51
1 year 6.74
Extreme 6.74
14.51
3 years 5.9
Extreme 5.9
53.08
5 years 5.9
Extreme 5.9
97.33
10 years 5.9
Extreme 5.9
108.46
Manager TitleAgeSince
Chief Executive Officer 47 11/02/2026
Director of Finance/CFO 56 23/06/2024
Chief Tech/Sci/R&D Officer 58 16/06/2024
Director TitleAgeSince
Chairman 66 14/06/2023
Director/Board Member 65 30/06/2018
Chairman 67 11/02/2026
Date Insider Type Main position Quantity % Market Cap. Importance
21/05/26 Sell

Chief Executive Officer

-2,209 0.0035%
11/05/26 Sell

Chief Financial Officer

-11,139 0.0174%
11/05/26 Sell

Chief Technology Officer

-11,108 0.0174%
Change 5-day change 1-year change 3-year change Capi.($)
+2.01%+0.60%-20.00%-46.44% 487M
+0.65%-3.36%+36.98%+60.50% 63.48B
+1.76%+1.27%+11.82%+81.21% 54.55B
-0.94%+0.99%+10.45%+100.19% 53.59B
+2.76%+0.87%+27.92%+55.07% 44.75B
+2.00%-3.39%+17.83%+119.04% 41.62B
+1.34%-2.86%+224.43%+914.08% 39.91B
+0.64%-3.95%+11.15%+45.57% 32.47B
+29.06%+47.63%+107.12%+92.73% 26.7B
+3.72%-6.23%+26.01%-2.99% 23.36B
Average +4.30%-0.15%+45.37%+141.90% 38.09B
Weighted average by Cap. +3.23%+0.17%+48.10%+161.20%

Financials

2026 *2027 *
Net sales 296M 266M 246M 222M 416M 28.2B 421M 2.94B 1.17B 14.76B 1.11B 1.09B 46.85B 64.19M 57.59M 53.25M 48.23M 90.1M 6.11B 91.19M 637M 254M 3.2B 241M 236M 10.16B
Net income -666K -598K -553K -501K -935K -63.47M -947K -6.61M -2.63M -33.21M -2.5M -2.45M -105M -248M -222M -206M -186M -348M -23.61B -352M -2.46B -979M -12.35B -930M -910M -39.21B
Net Debt -451M -404M -374M -339M -633M -42.93B -640M -4.47B -1.78B -22.46B -1.69B -1.66B -71.31B -307M -275M -255M -231M -431M -29.22B -436M -3.04B -1.21B -15.29B -1.15B -1.13B -48.55B
Projected Income Statement - Annual - Arvinas, Inc.
Logo Arvinas, Inc.
Arvinas, Inc. is a clinical-stage biotechnology company. The Company, through its PROteolysis Targeting Chimera (PROTAC) protein degrader platform, is pioneering the development of protein degradation therapies designed to harness the body's natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. It is progressing multiple investigational drugs through clinical development programs, including vepdegestrant, ARV-393, ARV-102, ARV-80, and ARV-027. Vepdegestrant is an investigational orally bioavailable PROTAC protein degrader designed to target and degrade the ER for the treatment of patients with locally advanced or metastatic ER+/HER2- breast cancer. It is co-developing vepdegestrant with Pfizer. ARV-393 is an investigational, orally bioavailable PROTAC to degrade BCL6, a transcriptional repressor and a regulator of normal B-cell maturation and differentiation processes. ARV-102 is in development to treat neurodegenerative diseases.
Employees
246
Date Price Change Volume
28/10/26 US$7.600 +2.01% 891,286
27/10/26 US$7.450 +1.92% 800,824
26/10/26 US$7.310 +0.14% 724,861
23/10/26 US$7.300 -5.44% 651,573
22/10/26 US$7.720 +2.18% 620,196
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
MarketScreener Ratings - Arvinas, Inc.
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
16
Last Close Price
7.600USD
Average target price
13.93USD
Spread / Average Target
+83.27%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Arvinas, Inc.
  1. Stock Market
  2. Stocks
  3. ARVN Stock